Wall Street Zen Upgrades Baird Medical Investment (NASDAQ:BDMD) to Hold

Baird Medical Investment (NASDAQ:BDMD) was upgraded by stock analysts at Wall Street Zen to a “hold” rating in a report released on Saturday.

Separately, Weiss Ratings reissued a “sell (d)” rating on shares of Baird Medical Investment in a research note on Tuesday, January 27th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has a consensus rating of “Sell”.

Baird Medical Investment Stock Performance

Shares of NASDAQ BDMD opened at $2.40 on Friday. The firm has a 50 day moving average price of $1.56 and a two-hundred day moving average price of $1.66. Baird Medical Investment has a 52-week low of $0.76 and a 52-week high of $7.26.

Institutional Investors Weigh In On Baird Medical Investment

A number of hedge funds have recently added to or reduced their stakes in BDMD. Geode Capital Management LLC lifted its stake in Baird Medical Investment by 59.7% in the second quarter. Geode Capital Management LLC now owns 25,442 shares of the company’s stock valued at $93,000 after buying an additional 9,511 shares during the period. Jane Street Group LLC bought a new stake in shares of Baird Medical Investment in the 2nd quarter valued at $142,000. Finally, Citadel Advisors LLC bought a new stake in shares of Baird Medical Investment in the 3rd quarter valued at $99,000. 19.78% of the stock is currently owned by institutional investors.

About Baird Medical Investment

Baird Medical Investment Holdings Ltd. is a medical technology company, which engages in the development and provision of medical devices. It is also involved in the design, development, manufacturing, and sale of microwave ablation medical devices, as well as sale of other medical devices. The company was founded on June 16, 2023 and is headquartered in Guangzhou, China.